Polypeptide libraries with a predetermined scaffold
| Title: | Polypeptide libraries with a predetermined scaffold |
|---|---|
| Patent Number: | 9,469,670 |
| Publication Date: | October 18, 2016 |
| Appl. No: | 12/735069 |
| Application Filed: | December 22, 2008 |
| Abstract: | Populations of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the scaffold amino acid sequence EXXXAXXEIX XLPNLTXXQX XAFIXKLXDD PSQSSELLSE AKKLNDSQ (SEQ ID NO: 1) or AKYAKEXXXAXX EIXXLPNLTX XQXXAFIXKL XDDPSQSSEL LSEAKKLNDS Q (SEQ ID NO:2), wherein each X individually corresponds to an amino acid residue which is varied in the population are disclosed. Also populations of polynucleotides, wherein each member encodes a member of a polypeptide population are disclosed. Furthermore, combinations of such polypeptide populations and such polynucleotide populations are disclosed, wherein each member of polypeptide population is physically or spatially associated with the polynucleotide encoding that member via means for genotype-phenotype coupling. |
| Inventors: | Abrahmsén, Lars (Bromma, SE); Herne, Nina (Stockholm, SE); Lendel, Christofer (Farsta, SE); Feldwisch, Joachim (Tyresö, SE) |
| Assignees: | AFFIBODY AB (Solna, SE) |
| Claim: | 1. A population of polypeptide variants based on a common scaffold, each polypeptide variant in the population comprising the scaffold amino acid sequence [table included] wherein each X individually is selected from any amino acid residue independent of the identity of any other residue denoted X, and wherein said population of polypeptide variants comprises at least 1×10 4 unique polypeptide variant sequences. |
| Claim: | 2. A population of polypeptide variants based on a common scaffold, each polypeptide variant in the population comprising the scaffold amino acid sequence [table included] wherein each X individually is selected from any amino acid residue is independent of the identity of any other residue denoted X, and wherein said population of polypeptide variants comprises at least 1×10 4 unique polypeptide variant sequences. |
| Claim: | 3. A population according to claim 1 , which comprises at least 1×10 6 unique polypeptide variant sequences. |
| Claim: | 4. A population according to claim 1 , which comprises at least 1×10 8 unique polypeptide variant sequences. |
| Claim: | 5. A population according to claim 1 , which comprises at least 1×10 10 unique polypeptide variant sequences. |
| Claim: | 6. A population according to claim 1 , which comprises at least 1×10 12 unique polypeptide variant sequences. |
| Claim: | 7. A population according to claim 1 , which comprises at least 1×10 14 unique polypeptide molecules variant sequences. |
| Claim: | 8. The population according to claim 1 , wherein each X individually is selected from the 20 naturally occurring amino acid residues. |
| Claim: | 9. The population according to claim 2 , wherein each X individually is selected from the 20 naturally occurring amino acid residues. |
| Patent References Cited: | 5831012 November 1998 Nilsson et al. 6534628 March 2003 Nilsson et al. 6602977 August 2003 Ljungqvist et al. 6740734 May 2004 Nilsson et al. 7993650 August 2011 Carlsson et al. 2009/0180954 July 2009 Marino et al. 2009/0191124 July 2009 Marino et al. 2011/0021424 January 2011 Lindborg et al. 2 077 272 July 2009 WO 91/01743 February 1991 WO 92/00091 January 1992 WO 95/19374 July 1995 WO 2005/003156 January 2005 2005097202 October 2005 WO2006092338 August 2006 WO 2007/065635 June 2007 WO2009019117 February 2009 WO 2009/077175 June 2009 WO 2009/077569 June 2009 2009080811 July 2009 WO 2009/080810 July 2009 |
| Other References: | Orlova, Anna et al., “Tumor Imaging Using a Picomolar Affinity HER2 Binding Affibody Molecule”, Cancer Research, vol. 66, No. 8., pp. 4339-4348 (Apr. 15, 2006). cited by applicant Wikman, M. et al., Election and characterization of HER2/neu-binding affibody ligands, Protein Engineering, Design & Selection, vol. 17, No. 5, pp. 455-462 (Jun. 18, 2004). cited by applicant Orlova, Anna et al., “Affibody Molecules for Molecular Imaging and Therapy for Cancer”, Cancer Biotherapy & Radiopharmaceuticals, vol. 22, No. 6, pp. 573-584 (2007). cited by applicant Orlova, Anna et al., “Synthetic Affbody Molecules: A Novel Class of Affinity Ligands for Molecular Imaging of HER2-Expressing Malignant Tumors”, Cancer Research, vol. 67, No. 5, pp. 2178-2186 (Mar. 1, 2007). cited by applicant Tran, Thuy et al., “99mTe-maEEE-ZHER2:342, an Affibody Molecule-Based Tracer for the Detection of HER2 Expression in Malignant Tumors”, Bioconjugate Chemistry, vol. 18, No. 6, pp. 1956-1964 (2007). cited by applicant Tolmachev, Vladimir et al., “Radionuclide Therapy of HER2-Positive Microxenografis Using a177 Lu-Labeled HER2-Specific Affibody Molecule”, Cancer Research, vol. 67, No. 6, (Mar. 15, 2007). cited by applicant Linhult, Martin et al., “Improving the Tolerance of a Protein A Analogue to Repeated Alkaline Exposures Using a Bypass Mutagenesis Approach”, Proteins, vol. 55, pp. 407-416 (2004). cited by applicant Nord, Karin et al., “Binding Proteins Selected From Combinatorial Libraries of an α-helical Bacterial Receptor Domain”, Nature Biotechnology, vol. 15, pp. 772-777 (1997). cited by applicant Gronwall et al. “Selection and Characterization of Affibody Ligands Binding to Alzheimer Amyloid β Peptides” Journal of Biotechnology, 128 (2007) 162-183. cited by applicant Nord et al. “Binding Proteins Selected from Combinatorial Libraries of an a-helical Bacterial Receptor Domain” Nature Biotechnology, vol. 15, pp. 772-777 (1997). cited by applicant Nord et al. “A Combinatorial Library of an a-helical Bacterial Receptor Domain” Protein Engineering, vol. 8, No. 6, pp. 601-608 (1995). cited by applicant Alvarez, et al. “Biology of Platelet-Derived Growth Factor and its Involvement in Disease” Mayo Clin Proc, Sep. 2006; vol. 81, No. 9, pp. 1241-1257. cited by applicant Baranowska-Kortylewicz et al. “Efect of Platelet-Derived Growth Factor Receptor-β Inhibition with STI157 on Radioimmunotherapy” Cancer Research 2005, vol. 65, No. 17, Sep. 1, 2005, pp. 7824-7831. cited by applicant Bohmer et al. “A Single Amino Acid Exchange Inverts Susceptibility of Related Receptor Tyrosine Kinases for the ATP Site Inhibitor STI-571*” The Journal of Biological Chemistry, 2003 vol. 278, No. 7, pp. 5148-5155. cited by applicant Hosse et al., “A New Generation of Protein Display Scaffolds for Molecular Recognition”, Protein Science; 15 (2006); pp. 14-27. cited by applicant “Phusion® Flash, High-Fidelity PCR Master Mix” Finnzymes Product Pamphlet ; Version 1.4; Oct. 2010; 2 Pages. cited by applicant International Search Report of the International Searching Authority for International Patent Application No. PCT/EP2008/068168; International filing Date: Dec. 22, 2008; Date of Mailing: Apr. 27, 2009. cited by applicant IPRP and Written Opinion of the International Searching Authority for International Patent Application No. PCT/EP2008/068168; International Filing Date: Dec. 22, 2008; Date of Mailing Jun. 22, 2010. cited by applicant Jones, et al. “Oncogenic derivatives of platelet-derived growth factor receptors” Celluar and Molecular Life Sciences, vol. 61, (2004) pp. 2912-2923. cited by applicant Levitzki “PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases” Cytokine & Growth Factor Reviews, vol. 15 (2004) pp. 229-235. cited by applicant Lindborg et al. “Engineered High-Affinity Affibody Molecules Targeting Platelet-Derived Growth Factor Receptor β In Vivo” Journal of Molecular Biology, (2011) vol. 407, pp. 298-315. cited by applicant Ostmanet al. “PDGF Receptors as Targets in Tumor Treatment” Advances in Cancer Research, 2007, vol. 97, pp. 247-274. cited by applicant Paulsson et al. “Prognostic Significance of Stromal Platelet-Derived Growth Factor β-Receptor Expression in Human Breast Cancer” The American Journal of Pathology, vol. 175, No. 1, Jul. 2009, pp. 334-341. cited by applicant Pietras et al. “PDGF receptors as cancer drug targets” Cancer Cell, May 2003, vol. 3, pp. 439-443. cited by applicant Rossi et al. “PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract” Histopathology 2005, vol. 46, pp. 522-531. cited by applicant Shen et al. “An antibody directed against PDGF receptor β enhances the antitumor and the anti-angiogenic activies of an anti-VEGF receptor 2 antibody” Biochemical and Biophysical Research Communications 357, (2007), pp. 1142-1147. cited by applicant Sörensen et al., “First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the 111 In-ABY-025 Affibody Molecule”, The Journal of Nuclear Medicine; 2014; 55; pp. 730-735. cited by applicant Tolmachev et al., “Imaging of Platelet-Derived Growth Factor Receptor β Expression in Glioblastoma Xenografts Using Affibody Molecule 111-In-DOTA-Z09591”, Journal of Nuclear Medicine, 2014, 55: 1-7; epublished on Jan. 9, 2014, as doi:10.2967/jnumed.11. cited by applicant |
| Primary Examiner: | Boesen, Christian |
| Attorney, Agent or Firm: | Cantor Colburn LLP |
| Accession Number: | edspgr.09469670 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|